(Q37942654)

25 August 2017

1 reference

title

Will new antimicrobials overcome resistance among Gram-negatives? (English)

1 reference

25 August 2017

main subject

Gram-negative bacteria

0 references

1

Matteo Bassetti

1 reference

25 August 2017

4

Lucia Taramasso

1 reference

25 August 2017

Francesca Ginocchio

2

1 reference

25 August 2017

Małgorzata Mikulska

series ordinal

3

1 reference

25 August 2017

Daniele Roberto Giacobbe

series ordinal

5

1 reference

25 August 2017

publication date

1 October 2011

1 reference

Expert Review of Anti-infective Therapy

25 August 2017

number of pages

14

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

25 August 2017

volume

9

1 reference

25 August 2017

issue

10

1 reference

25 August 2017

page(s)

909-922

1 reference

Current epidemiology of multidrug‐resistant gram‐negative bacilli in the United States

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Clinical and economic impact of common multidrug-resistant gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Promiscuous DNA: horizontal transfer of transposable elements and why it matters for eukaryotic evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

The spread of Klebsiella pneumoniae carbapenemases: a tale of strains, plasmids, and transposons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Evolution of beta-lactam biosynthesis genes and recruitment of trans-acting factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Extended-spectrum β-lactamases in Gram Negative Bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Emerging carbapenemases: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

A functional classification scheme for beta-lactamases and its correlation with molecular structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

The structure of β-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Resistance to polymyxins: Mechanisms, frequency and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

21 January 2018

Acinetobacter infection

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Fluoroquinolones: action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Aminoglycosides versus bacteria--a description of the action, resistance mechanism, and nosocomial battleground.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

New aminoglycoside antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Characterization of the fomA and fomB gene products from Streptomyces wedmorensis, which confer fosfomycin resistance on Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Ceftobiprole: a new broad spectrum cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Ceftaroline for complicated skin and skin-structure infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Current status of newer carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Doripenem: a new carbapenem antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Relation between the antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa from respiratory specimens and antimicrobial use density (AUD) from 2005 through 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144. I. Taxonomy, fermentation, isolation and structural elucidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

ME1036, a novel carbapenem, with enhanced activity against clinical isolates causing bacteraemic community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Resistance development profiling of piperacillin in combination with the novel {beta}-lactamase inhibitor BLI-489.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Pharmacodynamics of ceftazidime plus the serine beta-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Activity of a novel combination against multidrug-resistant nonfermenters: ceftazidime plus NXL104.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Metallo-beta-lactamases in Gram-negative bacteria: introducing the era of pan-resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

In vitro and in vivo properties of BAL30376, a β-lactam and dual beta-lactamase inhibitor combination with enhanced activity against Gram-negative Bacilli that express multiple β-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

The antibiotic development pipeline for multidrug‐resistant gram‐negative bacilli: current and future landscapes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Design and synthesis of potent Gram-negative specific LpxC inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Antimicrobial peptides: primeval molecules or future drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

Prospects for the next anti-Pseudomonas drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.107

21 January 2018

Identifiers

DOI

10.1586/ERI.11.107

1 reference

25 August 2017

1 reference